Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Radiation Oncology Associates, Burlington, Massachusetts.
Pract Radiat Oncol. 2024 Sep-Oct;14(5):e362-e372. doi: 10.1016/j.prro.2024.06.003. Epub 2024 Jul 4.
To assess whether a radiation therapy (RT) dose affects response in bulky tumors in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Data from patients with r/r DLBCL treated with salvage- or palliative-intent RT (2008-2020) at a single institution were examined. Index lesion size ≥7.5 cm was defined as bulky. Equivalent doses in 2-Gy fractions (EQD2) were calculated to compare doses between conventional and hypofractionated (≥2.5 Gy/fraction) schemes. Objective response rates (ORRs) were compared using nonparametric Mann-Whitney U test or Kruskal-Wallis test with Dunn's multiple comparison corrections. Freedom from local progression (FFLP) was assessed using Kaplan-Meier and Cox proportional hazard regression analyses.
One hundred eighty-three courses of 151 unique patients were included (salvage: 37% and palliative: 63%). Nonbulky and bulky tumors were irradiated in 109 (60%) and 74 (40%) courses, respectively. Median EQD2 was 33 Gy (IQR, 23-39 Gy) with hypofractionation in 84 (46%) cases. Of those with post-RT imaging (80%), the ORR was 59%, with a trend toward worsened ORR in bulky tumors (50% vs 65%, P = .077). For bulky tumors, RT regimens with EQD2s >30 Gy were associated with better ORR (≤30 Gy vs >30 Gy: 27% vs 64%, P = .0073), whereas a lower EQD2 cutoff was sufficient for nonbulky tumors (≤20 Gy vs >20 Gy: 38% vs 75%, P = .0011). On multivariable regression analysis, bulky tumor size was associated with worsened FFLP (hazard ratio, 2.07; 95% CI, 1.16-3.68; P = .014), whereas high EQD2s >30 Gy were associated with better FFLP (hazard ratio, 0.48; 95% CI, 0.25-0.93; P = .031). Bulky tumors treated with EQD2s ≤30 Gy had the lowest median FFLP (4.0 months), whereas EQD2s >30 Gy had an unreached median FFLP (P = .0047).
Bulky r/r DLBCL tumors were associated with less favorable tumor control outcomes in the salvage and palliative settings. RT regimens with higher EQD2s (>30 Gy) should be considered if durable local control of bulky tumors is desired.
评估放疗(RT)剂量是否会影响复发/难治性(r/r)弥漫性大 B 细胞淋巴瘤(DLBCL)中大块肿瘤的反应。
检查了 2008 年至 2020 年在单一机构接受挽救性或姑息性 RT 治疗的 r/r DLBCL 患者的数据。索引病变大小≥7.5cm 定义为大块肿瘤。使用等效剂量 2-Gy 分数(EQD2)计算来比较常规和低分割(≥2.5Gy/分数)方案之间的剂量。使用非参数曼-惠特尼 U 检验或克鲁斯卡尔-沃利斯检验与邓恩多重比较校正比较客观缓解率(ORR)。使用 Kaplan-Meier 和 Cox 比例风险回归分析评估无局部进展(FFLP)。
共纳入 151 名患者的 183 个疗程(挽救性:37%,姑息性:63%)。109 个(60%)和 74 个(40%)疗程分别对非大块和大块肿瘤进行了放疗。中位 EQD2 为 33Gy(IQR,23-39Gy),84 例(46%)采用低分割。在接受 RT 后影像学检查的 80%患者中,ORR 为 59%,大块肿瘤的 ORR 有恶化趋势(50% vs 65%,P=.077)。对于大块肿瘤,EQD2s>30Gy 的 RT 方案与更好的 ORR 相关(≤30Gy vs >30Gy:27% vs 64%,P=.0073),而对于非大块肿瘤,较低的 EQD2 截点就足够了(≤20Gy vs >20Gy:38% vs 75%,P=.0011)。多变量回归分析显示,大块肿瘤大小与较差的 FFLP 相关(风险比,2.07;95%CI,1.16-3.68;P=0.014),而 EQD2s>30Gy 与更好的 FFLP 相关(风险比,0.48;95%CI,0.25-0.93;P=0.031)。EQD2s≤30Gy 治疗的大块肿瘤中位 FFLP 最低(4.0 个月),而 EQD2s>30Gy 的中位 FFLP 尚未达到(P=0.0047)。
在挽救和姑息治疗中,大块 r/r DLBCL 肿瘤与肿瘤控制结局较差相关。如果需要对大块肿瘤进行持久的局部控制,应考虑使用 EQD2s>30Gy 的 RT 方案。